Synced daily from ClinicalTrials.gov via AACT. Last sync: .
11 Sparsentan clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 7 indications (including Focal Segmental Glomerulosclerosis & Immunoglobulin A Nephropathy) and 1,194 total planned enrollment. 2 Phase 3 Sparsentan trials and 5 Phase 2, 1 Phase 4 are listed. 5 Sparsentan clinical trials are actively recruiting at 26 U.S. sites across 16 states. Most recent activity: NCT07555301 (Dec 2029).
Where to Participate: All Sparsentan Trial Sites in the U.S. (26 sites across 16 states)
Every actively recruiting Sparsentantrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
11 Sparsentan clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants. 4 are marked completed.
Are Sparsentan clinical trials recruiting in 2026?
Yes — 3 Sparsentan trials are actively recruiting in 2026, with 26 U.S. sites across 16 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Sparsentan being studied for?
Sparsentan is being studied for Focal Segmental Glomerulosclerosis, Immunoglobulin A Nephropathy, Proteinuria, Kidney Diseases, Glomerulonephritis and 15 more. The trials are grouped by indication on this page.
What phase is Sparsentan in?
Sparsentan clinical trials span 1 Phase 4, 2 Phase 3, 5 Phase 2, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Sparsentan clinical trials?
The lead sponsor across the most Sparsentan trials is Travere Therapeutics, Inc., with 4 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Sparsentanas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.